# UK and EU Reshape Medtech Tender Rules

A Ropes & Gray analysis describes changing medical-device market-access and compliance rules across the United Kingdom and European Union, with consequences for suppliers seeking National Health Service (NHS) business. NHS contractors should confirm Evergreen Level 1 eligibility now. For larger contracts from April 2027, suppliers should prepare board-approved plans addressing relevant global Scope 3 emissions, with measurable progress expected by 2030. Manufacturers also need to reassess regulatory pathways and product portfolios, alongside board oversight of anti-corruption, cybersecurity, and AI obligations.

- Suppliers pursuing NHS contracts can confirm Evergreen Level 1 eligibility now and incorporate the upcoming sustainability-plan expectations into bids for larger contracts from April 2027.
- The April 2027 start is roughly five months away; companies should identify relevant global Scope 3 emissions and prepare board-approved plans. The signal also identifies measurable progress by 2030.
- Medical-device manufacturers should reassess UK and EU regulatory pathways and product portfolios, and review board oversight of anti-corruption, cyber, and AI obligations that may affect market access and tender eligibility.

**Jurisdictions:** international
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** November 17, 2026

### Government Entities
- National Health Service (NHS)
- Medicines and Healthcare products Regulatory Agency (MHRA)
- European Union (EU)

### Sources
- [Redrawing the Medtech Map: Why Compliance Is Now a Strategic Question | Ropes & Gray LLP - JDSupra](https://www.jdsupra.com/legalnews/redrawing-the-medtech-map-why-3328748) - JD Supra